Early clinical trials with Monalizumab alone or in combination with anti-PD-L1 antibodies like Durvalumab have demonstrated acceptable safety profiles and preliminary signs of immune activation, the COAST study reported improved overall response rates (ORR) and progression-free survival (PFS) with Monalizumab and Durvalumab in unresectable stage III NSCLC patients (48). Here, CD274 is linked to non-small cell lung carcinoma.